Showing 3561-3570 of 4075 results for "".
- UCB’s Bimekizumab Performs Well in PsA Studieshttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-psa-studies/2461460/Two new studies highlight the efficacy and safety of bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and/or tumor necrosis factor inhibitor inadequate responders (TNFi-IR). The 24-week results from the Phase 3 BE OPTIMAL study and 16-w
- Garnier Debuts Product Impact Ranking Across Hair Care Rangehttps://practicaldermatology.com/news/garnier-debuts-product-impact-ranking-across-hair-care-range/2461455/Garnier is launching a digital labeling system that ranks its hair care products versus other L'Oreal Group Products based on 14 environmental factors. Product Impact Labelling ranks each product from A to E, with "A" indicating the 10% of L'Oreal Group Products in the
- DermTech, Sonora Quest Laboratories Join Forces Expand Access to Melanoma Detection Test in Arizonahttps://practicaldermatology.com/news/dermtech-sonora-quest-laboratories-join-forces-expand-access-to-melanoma-detection-test-in-arizona/2461434/Sonora Quest is the exclusive laboratory offering the DermTech Melanoma Test for all of Arizona. The DermTech Melanoma Test uses a non-invasive Smart Sticker to lift skin cells from the surface of a patient’s skin to be tested for select genomic markers associated with melanoma. I
- Reistone Biopharma's Oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for ADhttps://practicaldermatology.com/news/reistone-biopharmas-oral-ivarmacitinib-meets-primary-endpoint-in-phase-iii-study-for-ad/2461431/Reistone Biopharma’s once daily Ivarmacitinib as monotherapy relieves in improving skin inflammation and itchiness n adults and adolescents with moderate-to-severe, according to a results from thePhase III QUARTZ3 study. The study evaluated the efficacy and safety of once dai
- Nivolumab Shows Promise in Advanced SCChttps://practicaldermatology.com/news/nivolumab-shows-promise-in-advanced-scc/2461399/Numerous studies have shown that immune checkpoint inhibitors can boost the immune system’s response against various cancers, and now, a phase II clinical trial has demonstrated that patients with advanced cutaneous squamous cell carcinoma can benefit from nivolumab. The research is publish
- Phase 3 Data: Opdivo Reduced Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/phase-3-data-opdivo-reduced-risk-of-recurrence-or-death-by-58-versus-placebo-in-patients-with-completely-resected-stage-iib-or-iic-melanoma/2461391/Bristol Myers Squibb shared results from the Phase 3 CheckMate -76K trial, in which Opdivo (nivolumab) as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo in patients with completely resected stage IIB
- Skin Microbiome Linked to GVHD Following Stem Cell Transplant in Leukemiahttps://practicaldermatology.com/news/skin-microbiome-linked-to-gvhd-following-stem-cell-transplant-in-leukemia/2461385/Organ damage occurs in up to 70 percent of patients in the first few months following stem cell transplant, but the precise reasons for this potentially life-threatening reaction haven’t been fully understood. Now, researchers led by Georg Stary from the Department of Dermatology at MedUni
- ASDSA's 2022 Top Advocates Recognizedhttps://practicaldermatology.com/news/asdsas-2022-top-advocates-recognized/2461381/Meet the American Society for Dermatologic Surgery Association (ASDSA) honorees from the fourth annual Top Advocate program Honorees are chosen based on their contribution to various advocacy efforts throughout the year and demonstrated commitment to patient safety in the field of derma
- Hugel Resubmits Botulax BLA to FDAhttps://practicaldermatology.com/news/hugel-resubmits-botulax-bla-to-fda-1/2461380/Hugel resubmitted the BLA for its botulinum toxin called Botulax for smoothing glabellar lines to the U.S. FDA. Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) to advance into the U.S. market i
- DermTech Presents on Value of Decentralization of Clinical Trialshttps://practicaldermatology.com/news/dermtech-presents-on-value-of-decentralization-of-clinical-trials/2461368/Technology can help decentralize clinical trials, leading to greater patient satisfaction, a more diverse patient population, better retention and cost savings, according to a presentation by DermTech at Outsourcing in Clinical Trials Southern California, held from Sept. 28-29 in San Di